Herpes zoster during treatment with arsenic trioxide

Annals of Hematology

Volumn 83, Issue 3, 2004, Pages 198-200

  Tanvetyanon, T ^a,b   Nand, S ^b  

^a Cardinal Bernardin Cancer Centre   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Arsenic trioxide; Herpes zoster; Immunosuppresion; Opportunistic infection; Side effect

Indexed keywords

ANTIVIRUS AGENT; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; ARSENITE SODIUM; ARSPHENAMINE; CYTARABINE; DAUNORUBICIN; FAMCICLOVIR; NEOARSPHENAMINE; RETINOIC ACID;

ADULT; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CASE REPORT; CELLULAR IMMUNITY; COUGHING; DERMATITIS; DRUG MECHANISM; DRUG RESPONSE; FATIGUE; FEMALE; FEVER; HEADACHE; HELPER CELL; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IN VIVO STUDY; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOCYTOSIS; MALE; NAUSEA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RASH;

2-AMINOPURINE; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ARSENICALS; FEMALE; HERPES ZOSTER; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; TREATMENT OUTCOME;

EID: 1442301626     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0749-3     Document Type: Article

References (23)

1. Cohen JI, Brunell PA, Straus SE, Krause PR (1999) Recent advances in varicella-zoster virus infection. Ann Intern Med 130:922-932
2. Gnann JW Jr, Whitley RJ (2002) Herpes zoster. N Engl J Med 347:340-346
3. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860
4. Seinen W, Penninks A (1979) Immune suppression as a consequence of a selective cytotoxic activity of certain organometallic compounds on thymus and thymus-dependent lymphocytes. Ann N Y Acad Sci 320:499-517
5. Harrison MT, McCoy KL (2001) Immunosuppression by arsenic: a comparison of cathepsin L inhibition and apoptosis. Int Immunopharmacol 1(4):647-656
6. De la Fuente H, Portales-Perez D, Baranda L, Diaz-Barriga F, Saavedra-Alanis V, Layseca E, et al (2002) Effect of arsenic, cadmium and lead on the induction of apoptosis of normal human mononuclear cells. Clin Exp Immunol 129(1):69-77
7. Yu HS, Liao WT, Chang KL, Yu CL, Chen GS (2002) Arsenic induces tumor necrosis factor alpha release and tumor necrosis factor receptor 1 signaling in T helper cell apoptosis. J Invest Dermatol 119(4):812-819
8. Turelli P, Doucas V, Craig E, Mangeat B, Klages N, Evans R, et al (2001) Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Mol Cell 7(6):1245-1254
9. Berthoux L, Towers GJ, Gurer C, Salomoni P, Pandolfi PP, Luban J (2003) As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol 77(5):3167-3180
10. Shao W, Fanelli M, Ferrara FF et al (1998) Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR. α protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124-133
11. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62(14):3893-3903
12. Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6[Suppl 2]: 3-10
13. Camacho LH, Soignet SL, Chanel S, et al (2000) Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18:2620-2625
14. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, et al (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98(2):266-271
15. Bartolome B, Cordoba S, Nieto S, Fernandez-Herrera J, Garcia-Diez A (1999) Acute arsenic poisoning: clinical and histopathological features. Br J Dermatol. 141(6):1106-1109
16. Serrano M, Sainz de Aja E (1911) Zonas y herpes como efectos de la medicacion por salvarsan. Actas Dermosifiliograf 3:406-409
17. Package insert (2001) Trisenox (arsenic trioxide). Cell Therapeutics, Seattle, WA
18. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, et al (2001) Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97(1):264-269
19. Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, et al (2002) Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 39[Suppl 1]: 22-26
20. Murgo AJ (2001) Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 6[Suppl 2]: 22-28
21. Christian CW, Singer ML, Crawford JE, Durbin D (1997) Perianal herpes zoster presenting as suspected child abuse. Pediatrics 99(4):608-610
22. Franken RA, Franken M (2000) Pseudo-myocardial infarction during an episode of herpes zoster. Arq Bras Cardiol 75(6):523-530
23. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al (1995) Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123(2):89-96